https://www.reddit.com/r/shroomstocks/
https://www.reddit.com/r/shroomstock...billion_after/
https://www.bloomberg.com/news/artic...rnd=markets-vp
IPOn av Compass Pathways (CMPS) lär sannolikt leda till att de är övervärderade initialt, och där jag spår -extrem- volatilitet den kommande tiden.
Förs en rätt så seriös debatt där på Reddit /shroomstocks bl.a. om diverse aktier som lär explodera om en ny behandling blir tillgänglig bl.a. mot diverse psykiatriska åkommor. Compass Pathways, har bl.a. patenterat en av psilocybin-utvinningsteknikerna som potentiellt kan resultera i ett fullskaligt monopol om de får psilocybin-assisterad psykoterapi godkänd.
Förtillfället är de i FAS-2b, men jag är starkt övertygad, baserat på senaste forskningen inom neurobiologi och kring psykiatri att psilocybin kommer bli godkänt som behandling mot behandlingsresistent-depression (TRD*).
Psychedelics Promote Structural and Functional Neural Plasticity
https://www.sciencedirect.com/scienc...11124718307551
Finns mer detaljerad forskning i tråden nedan med studier för dem som är intresserade!
(FB) Psilocybin - bättre än SSRI i dagsfärsk studie mot depression
Potentialen är enorm, då en stor del av antidepressiva ej fungerar för kliniskt deprimerade, som oftast roterar mellan olika antidepressiva i förhoppning om att hitta något som fungerar adekvat.
Ett annat bolag som också sysslar med produktionen av psykedeliska mediciner är bl.a. Numinus (NUMI)
https://numinus.ca/
Lite kort om bolaget
Det exceptionellt -intressanta- i sammanhanget med Numinus, är att de har utfärdat warranter, med en löptid på september 10, 2022, som ger en rätten att köpa en aktie för 0.35$.. https://thedalesreport.com/business/2687/
Ett annat bolag är Mindmed (MMED, MMEDF)
https://www.mindmed.co/
De har en rätt så intressant pipeline av kandidater, mot bl.a. ångest, Hortons huvudvärk, ADHD, opiatberoenden etc*
Det är intressant att ämna att de tänker att minimera risken för snedtrippar genom att köra kombinationsterapi av LSD+MDMA, en kombo som känd som en candyflip i psych-kulturen.
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
https://www.prnewswire.com/news-rele...301065872.html
Ett till bolag är Champignonbrands (SHRM, SHRMF)
https://champignonbrands.com/
De försöker bl.a. utveckla psilocybin-assisterad-psykoterapi mot depression & PTSD.. Hittar ingen närmare information än så..
Psilocin Pharma Corp
https://www.psilocinpharma.com/
Om bolaget
Blev tidigare i år uppköpt av Revive Therapeutics Ltd.
Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.
https://www.globenewswire.com/news-r...arma-Corp.html
https://www.reddit.com/r/shroomstock...billion_after/
https://www.bloomberg.com/news/artic...rnd=markets-vp
IPOn av Compass Pathways (CMPS) lär sannolikt leda till att de är övervärderade initialt, och där jag spår -extrem- volatilitet den kommande tiden.
Förs en rätt så seriös debatt där på Reddit /shroomstocks bl.a. om diverse aktier som lär explodera om en ny behandling blir tillgänglig bl.a. mot diverse psykiatriska åkommor. Compass Pathways, har bl.a. patenterat en av psilocybin-utvinningsteknikerna som potentiellt kan resultera i ett fullskaligt monopol om de får psilocybin-assisterad psykoterapi godkänd.
Förtillfället är de i FAS-2b, men jag är starkt övertygad, baserat på senaste forskningen inom neurobiologi och kring psykiatri att psilocybin kommer bli godkänt som behandling mot behandlingsresistent-depression (TRD*).
Psychedelics Promote Structural and Functional Neural Plasticity
https://www.sciencedirect.com/scienc...11124718307551
Finns mer detaljerad forskning i tråden nedan med studier för dem som är intresserade!
(FB) Psilocybin - bättre än SSRI i dagsfärsk studie mot depression
Potentialen är enorm, då en stor del av antidepressiva ej fungerar för kliniskt deprimerade, som oftast roterar mellan olika antidepressiva i förhoppning om att hitta något som fungerar adekvat.
Ett annat bolag som också sysslar med produktionen av psykedeliska mediciner är bl.a. Numinus (NUMI)
https://numinus.ca/
Lite kort om bolaget
Numinus is at the forefront of addressing the growing prevalence of mental health issues and desire for greater wellness.
Numinus has received Health Canada approval to amend the Company’s existing licence under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind.
With this regulatory approval, Numinus is able to proceed with the production of naturally sourced, sustainable psilocybin for research purposes that will support the emerging field of psychedelic-assisted psychotherapy and research, at lower costs to currently produced synthetic psilocybin. The licence also allows Numinus to develop and licence its own exclusive IP for further product development in partnership with leading research organizations — something the research community has been seeking to secure.
The company’s existing licence (in alignment with licence holder Salvation Botanicals Ltd) allows Numinus to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT, and mescaline.
Numinus is dedicated to providing access to therapies that enhance and supplement existing options. Psychedelics will be part of this but will only be available for treatment once approved by regulators and governing bodies.
Numinus has received Health Canada approval to amend the Company’s existing licence under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind.
With this regulatory approval, Numinus is able to proceed with the production of naturally sourced, sustainable psilocybin for research purposes that will support the emerging field of psychedelic-assisted psychotherapy and research, at lower costs to currently produced synthetic psilocybin. The licence also allows Numinus to develop and licence its own exclusive IP for further product development in partnership with leading research organizations — something the research community has been seeking to secure.
The company’s existing licence (in alignment with licence holder Salvation Botanicals Ltd) allows Numinus to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT, and mescaline.
Numinus is dedicated to providing access to therapies that enhance and supplement existing options. Psychedelics will be part of this but will only be available for treatment once approved by regulators and governing bodies.
Det exceptionellt -intressanta- i sammanhanget med Numinus, är att de har utfärdat warranter, med en löptid på september 10, 2022, som ger en rätten att köpa en aktie för 0.35$.. https://thedalesreport.com/business/2687/
Numinus Wellness Inc (TSXV:NUMI) announced that the TSX Venture Exchange has accepted for listing the 9,200,000 warrants issued pursuant to the Company’s previously announced prospectus offering that closed on September 10, 2020. The Warrants will be listed for trading on the TSXV under the symbol “NUMI.WT” effective at market open on Monday, September 21, 2020.
Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.35 until September 10, 2022.
Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.35 until September 10, 2022.
Ett annat bolag är Mindmed (MMED, MMEDF)
https://www.mindmed.co/
De har en rätt så intressant pipeline av kandidater, mot bl.a. ångest, Hortons huvudvärk, ADHD, opiatberoenden etc*
LSD - ångest - FAS2B
LSD - Hortons huvudvärk - FAS2A
LSD- Mikrodosering, vuxen ADHD - FAS2A påbörjas Q42020
18-MC- Opiat abstinens & beroende - FAS2A
MDMA - FAS1A - MDMA+LSD (candyflip)
DMT - FAS1A
LSD - Hortons huvudvärk - FAS2A
LSD- Mikrodosering, vuxen ADHD - FAS2A påbörjas Q42020
18-MC- Opiat abstinens & beroende - FAS2A
MDMA - FAS1A - MDMA+LSD (candyflip)
DMT - FAS1A
Det är intressant att ämna att de tänker att minimera risken för snedtrippar genom att köra kombinationsterapi av LSD+MDMA, en kombo som känd som en candyflip i psych-kulturen.
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
https://www.prnewswire.com/news-rele...301065872.html
Ett till bolag är Champignonbrands (SHRM, SHRMF)
https://champignonbrands.com/
De försöker bl.a. utveckla psilocybin-assisterad-psykoterapi mot depression & PTSD.. Hittar ingen närmare information än så..
Psilocin Pharma Corp
https://www.psilocinpharma.com/
Om bolaget
About Psilocin Pharma Corp.
Psilocin has developed patent-pending formulation and production solutions for the active compound Psilocybin. The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations. Psilocin has developed formulations to date which include the Hydroxy Line. The line will include PSY-0.1 -Capsules- PSY-0.2 -Sublingual Spray- PSY-0.3 -Gel Cap- PSY-0.4/0.5 -Effervescent Tablets-and PSY-0.6 -Breath Strips. The precisely dosed formulations will work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to U.S. Food and Drug Administration (“FDA”) approval in the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and a number of other diseases. Psilocin’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption.
Psilocin has filed key provisional patent applications with the U.S. Patent and Trademark Office that cover methods of production of Psilocybin-based formulations. This includes sublingual sprays, effervescent tablets, hard-shell capsules, sublingual and transmucosal delivery systems (i.e. gum drops, oral strips, dosing pens). Furthermore, Psilocin has a patent-pending portfolio that includes Psilocybin extraction and crystallization methodologies. Specifically, the Psilocin patent applications relate to the following:
Solid Oral Pharmaceutical Compositions, United States Provisional Application Serial No. 62/985,052 - Psilocybin effervescent and psilocybin tablet designed to be placed under the tongue or dissolved in water. Allowing for improved taste and controlled release profiles.
Pharmaceutical Capsule Compositions, United States Provisional Application Serial No. 62/985,070 - Psilocybin hard-shell capsules containing dry, powdered ingredients in 2-piece capsules. Allowing for contemporary consumption familiar to the user (Gelatin and vegetarian enclosure options in addition to unique nutrient delivery combination options).
Pharmaceutical Gumdrop Compositions, United States Provisional Application Serial No. 62/985,084 - Psilocybin gum drops for improved administration of compounds. Offers unique delivery methods for fat and water soluble options.
Thin-Film Pharmaceutical Delivery System and Formulations, United States Provisional Application Serial No. 62/985,098 - Psilocybin oral strips and psilocybin transmucosal delivery system. Proprietary oral fast-dissolving drug delivery system rapidly releases though the buccal pathway.
Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration, United States Provisional Application Serial No. 62/984,590 - Formulation for spray/pump/dosing pen.
Methods for the Extraction and Crystallization of Psilocybin, United States Provisional Application Serial No. 62/985,360 - Psilocybin extraction and psilocybin re-crystallization method patent allows for the extraction of Psilocybin from raw form of magic mushrooms or magic truffles. Psilocin’s proprietary extraction process allows for the extraction of whole fungi extract with the option to selectively pull out pure Psilocybin Isolate in the downstream process.
Revive intends to take advantage of a number of regulatory incentives awarded by the FDA, such as orphan drug, fast track, breakthrough therapy and rare pediatric disease designations, and will also categorize opportunities that have FDA priority review voucher potential, which historically have been valued between $67.5 and $350 million. This strategy is complementary to Revive’s cannabinoid-based pharmaceutical portfolio, specifically clinical development of Cannabidiol in the treatment of Autoimmune Hepatitis, which already has FDA orphan drug designation. Revive is currently in the process of preparing an investigational new drug application for submission to the FDA.
Psilocin has developed patent-pending formulation and production solutions for the active compound Psilocybin. The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations. Psilocin has developed formulations to date which include the Hydroxy Line. The line will include PSY-0.1 -Capsules- PSY-0.2 -Sublingual Spray- PSY-0.3 -Gel Cap- PSY-0.4/0.5 -Effervescent Tablets-and PSY-0.6 -Breath Strips. The precisely dosed formulations will work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to U.S. Food and Drug Administration (“FDA”) approval in the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and a number of other diseases. Psilocin’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption.
Psilocin has filed key provisional patent applications with the U.S. Patent and Trademark Office that cover methods of production of Psilocybin-based formulations. This includes sublingual sprays, effervescent tablets, hard-shell capsules, sublingual and transmucosal delivery systems (i.e. gum drops, oral strips, dosing pens). Furthermore, Psilocin has a patent-pending portfolio that includes Psilocybin extraction and crystallization methodologies. Specifically, the Psilocin patent applications relate to the following:
Solid Oral Pharmaceutical Compositions, United States Provisional Application Serial No. 62/985,052 - Psilocybin effervescent and psilocybin tablet designed to be placed under the tongue or dissolved in water. Allowing for improved taste and controlled release profiles.
Pharmaceutical Capsule Compositions, United States Provisional Application Serial No. 62/985,070 - Psilocybin hard-shell capsules containing dry, powdered ingredients in 2-piece capsules. Allowing for contemporary consumption familiar to the user (Gelatin and vegetarian enclosure options in addition to unique nutrient delivery combination options).
Pharmaceutical Gumdrop Compositions, United States Provisional Application Serial No. 62/985,084 - Psilocybin gum drops for improved administration of compounds. Offers unique delivery methods for fat and water soluble options.
Thin-Film Pharmaceutical Delivery System and Formulations, United States Provisional Application Serial No. 62/985,098 - Psilocybin oral strips and psilocybin transmucosal delivery system. Proprietary oral fast-dissolving drug delivery system rapidly releases though the buccal pathway.
Pharmaceutical Formulations and Methods for Sublingual and Buccal Administration, United States Provisional Application Serial No. 62/984,590 - Formulation for spray/pump/dosing pen.
Methods for the Extraction and Crystallization of Psilocybin, United States Provisional Application Serial No. 62/985,360 - Psilocybin extraction and psilocybin re-crystallization method patent allows for the extraction of Psilocybin from raw form of magic mushrooms or magic truffles. Psilocin’s proprietary extraction process allows for the extraction of whole fungi extract with the option to selectively pull out pure Psilocybin Isolate in the downstream process.
Revive intends to take advantage of a number of regulatory incentives awarded by the FDA, such as orphan drug, fast track, breakthrough therapy and rare pediatric disease designations, and will also categorize opportunities that have FDA priority review voucher potential, which historically have been valued between $67.5 and $350 million. This strategy is complementary to Revive’s cannabinoid-based pharmaceutical portfolio, specifically clinical development of Cannabidiol in the treatment of Autoimmune Hepatitis, which already has FDA orphan drug designation. Revive is currently in the process of preparing an investigational new drug application for submission to the FDA.
Blev tidigare i år uppköpt av Revive Therapeutics Ltd.
Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.
https://www.globenewswire.com/news-r...arma-Corp.html